(Q38014498)

27 August 2017

Treatment options for unresectable neuroendocrine liver metastases (English)

1 reference

27 August 2017

Biku Joseph John

1

1 reference

PubMed ID

22646257

27 August 2017

Brian R Davidson

series ordinal

2

1 reference

27 August 2017

1 June 2012

1 reference

Expert Review of Gastroenterology & Hepatology

27 August 2017

1 reference

27 August 2017

6

1 reference

27 August 2017

3

1 reference

27 August 2017

357-369

1 reference

Gastroenteropancreatic neuroendocrine tumours

27 August 2017

1 reference

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

Carcinoid TumorsAn analysis of 2837 cases

21 January 2018

1 reference

Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary

21 January 2018

1 reference

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

21 January 2018

1 reference

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?

21 January 2018

1 reference

21 January 2018

1 reference

Therapeutic options for gastrointestinal carcinoids

21 January 2018

1 reference

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.

21 January 2018

1 reference

Neuroendocrine tumors. Biotherapy

21 January 2018

1 reference

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma

21 January 2018

1 reference

Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors

21 January 2018

1 reference

The pathophysiological consequences of somatostatin receptor internalization and resistance

21 January 2018

1 reference

Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis

21 January 2018

1 reference

Treatment of metastatic disease in patients with neuroendocrine tumors

21 January 2018

1 reference

Treatment of carcinoid liver metastases by hepatic-artery embolisation

21 January 2018

1 reference

Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours

21 January 2018

1 reference

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival

21 January 2018

1 reference

Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome

21 January 2018

1 reference

Radioembolization of liver tumors with yttrium-90 microspheres

21 January 2018

1 reference

Management of advanced neuroendocrine tumors with hepatic metastasis

21 January 2018

1 reference

Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead

21 January 2018

1 reference

Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors

21 January 2018

1 reference

Radiofrequency ablation treatment of refractory carcinoid hepatic metastases

21 January 2018

1 reference

Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy

21 January 2018

1 reference

OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy

21 January 2018

1 reference

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

21 January 2018

1 reference

High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience

21 January 2018

1 reference

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors

21 January 2018

1 reference

Management of neuroendocrine tumors: a meeting of experts from Latin America

21 January 2018

1 reference

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

21 January 2018

1 reference

Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin

21 January 2018

1 reference

Apoptosis in neuroendocrine tumours

21 January 2018

1 reference

The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours

21 January 2018

1 reference

Endocrine tumours of the gastrointestinal tract: Chemotherapy

21 January 2018

1 reference

Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin

21 January 2018

1 reference

Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors

21 January 2018

1 reference

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.

21 January 2018

1 reference

Hepatic neuroendocrine metastases: chemo- or bland embolization?

21 January 2018

1 reference

Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours

21 January 2018

1 reference

Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization

21 January 2018

1 reference

90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.

21 January 2018

1 reference

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

21 January 2018

1 reference

Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases

21 January 2018

1 reference

Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study

21 January 2018

1 reference

Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival.

21 January 2018

1 reference

Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization.

21 January 2018

1 reference

Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival

21 January 2018

1 reference

Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience

21 January 2018

1 reference

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

21 January 2018

1 reference

99mTc-Hynic-annexin V imaging to evaluate inflammation and apoptosis in rats with autoimmune myocarditis

21 January 2018

1 reference

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

21 January 2018

1 reference

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

21 January 2018

1 reference

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

21 January 2018

1 reference

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors

21 January 2018

1 reference

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

21 January 2018

1 reference

A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study

21 January 2018

1 reference

Endocrine pancreatic tumors: factors correlated with survival

21 January 2018

1 reference

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

21 January 2018

1 reference

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EGH.11.60

1 reference

release_zt4qsp2cjbc4rlj5upikoinjge

27 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zt4qsp2cjbc4rlj5upikoinjge

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

22646257

1 reference

PubMed ID

22646257